Mediator release, synthesis of some newly formed mediators, airway smooth muscle contraction, and nerve-impulse conduction are all dependent on the availability and flux of Ca2+. It is likely that Ca2+ antagonists modify allergic bronchoconstriction. Ca2+ antagonists in vitro have been shown to inhibit synthesis and/or release of mediators and attenuate airway smooth muscle contraction. In vivo effects of Ca2+ antagonists are variable. Currently available Ca2+ antagonists are of limited value in the treatment of asthma. It is hoped that newer potent agents when administered via inhaled route may be of potential use.
|Original language||English (US)|
|Number of pages||16|
|Journal||Immunology and Allergy Clinics of North America|
|State||Published - Jan 1 1990|
ASJC Scopus subject areas
- Immunology and Allergy